Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 3Paraproteinemias 1Amyloidosis 1Alzheimer Disease 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × birtamimab × Clear all
NCT02613182 2019-05-16

OLE

Prothena Biosciences Ltd.

Phase 2 Terminated
34 enrolled 10 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed
129 enrolled 18 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

NCT03154047 2019-03-26

Study in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 2 Terminated
80 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡